For the first time in the world, the Food and Drug Administration (FDA) has approved the use of a medical product based on the extracellular matrix of the umbilical cord for the treatment of wounds. This is the world’s first medical product created from the extracellular matrix of the human umbilical cord, intended for the treatment of acute and chronic wounds.
The product based on the umbilical cord can be used in the treatment of wounds, bedsores, diabetic ulcers, surgical and traumatic injuries.
The therapeutic effect of this medical product is based on the fact that it serves as a natural matrix that imitates the natural environment for cells in the body. Corplex P is created from such elements as collagen and glycosaminoglycans, which support cell growth and tissue regeneration.
There is an increased demand for drugs for the treatment of wounds due to the aging of the population, a sharp increase in the incidence of diabetes and obesity in the world.
The search for effective wound treatment methods is more relevant than ever in Ukraine because of the war with Russia. Scientists of the Institute of Cell Therapy have developed a method of treating gunshot and mine-explosive wounds using the amniotic membrane obtained from the placenta. The latter has been successfully used in Ukraine for a long time in ophthalmic operations.
